These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30886963)

  • 21. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
    Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
    Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
    Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
    Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis.
    Roseman C; Truedsson L; Kapetanovic MC
    Arthritis Res Ther; 2012 Jul; 14(4):R170. PubMed ID: 22824238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
    Rodgers GL; Esposito S; Principi N; Gutierrez-Brito M; Diez-Domingo J; Pollard AJ; Snape MD; Martinón-Torres F; Gruber WC; Patterson S; Thompson A; Gurtman A; Paradiso P; Scott DA
    Vaccine; 2013 Oct; 31(42):4765-74. PubMed ID: 23965217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
    Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
    Front Immunol; 2021; 12():791147. PubMed ID: 34987514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
    Mori S; Ueki Y; Ishiwada N
    Mod Rheumatol; 2023 Mar; 33(2):312-317. PubMed ID: 35348759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
    Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
    Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
    Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.
    Mori S; Ueki Y; Akeda Y; Hirakata N; Oribe M; Shiohira Y; Hidaka T; Oishi K
    Ann Rheum Dis; 2013 Aug; 72(8):1362-6. PubMed ID: 23345600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial.
    Nguyen MTT; Lindegaard H; Hendricks O; Jørgensen CS; Kantsø B; Friis-Møller N
    J Rheumatol; 2017 Dec; 44(12):1794-1803. PubMed ID: 28966211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
    Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
    Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
    Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
    BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.